CLINICAL ROLE -
An Overview of ABSSSI and Its Associated Economic Burden
Watch
How Technology Can Foster a Seamless Patient Care Continuum
Innovations such as the Apple iPhone HealthKit could help create a smooth transition throughout the patient journey all the way to the specialty pharmacy.
Read More
World's First Smart Inhaler is Arriving
Teva has just unveiled the world's first integrated smart inhaler to the market.
Antiretroviral Therapy Adherence Crucial for Undetectable Equals Untransmittable Method in HIV
An overview of scientific evidence supporting the HIV undetectable=untransmittable concept and implications for HIV prevention and treatment.
Trending News Today: Study Links Opioid Marketing to Rise in Overdose Deaths
Top news of the day across the health care landscape.
Trending News Today: Walmart, CVS Reach Agreement on Pharmacy Network Deal
Three New Strains of Hepatitis C Virus Create Greater Challenges
Clear differences in hepatitis C virus worldwide indicate the need to increase global understanding of the virus.
CDC: Seasonal Influenza Activity Remains Elevated
Overall, 3.1% of people in the United States sought treatment from their health care providers for flu-like illness during the week ended January 12, 2019.
Study Shows Opioid Deaths May be Linked to Drug Marketing
Opioid abuse is considered a major public health issue across the country.
Ibrutinib Superior to Chemoimmunotherapy for Progression-Free Survival in Older CLL Patients
Study suggests a survival benefit with ibrutinib compared with chemoimmunotherapy bendamustine plus rituximab in patients with chronic lymphocytic leukemia.
FDA OKs Third Trastuzumab Biosimilar
Officials with the FDA approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.
Monday Pharmaceutical Mystery: January 21
Can you solve the pharmaceutical mystery?
Trending News Today: FDA Commissioner Says Level of E-Cigarette Addiction May Warrant Drug Therapy
Trending News Today: Lilly Cancer Drug Fails to Improve Survival in Clinical Trial
Adverse Effect-Related Deaths Decline in United States
From 1990 to 2016, the rate of deaths due to adverse effects of medical treatment decreased 21.4% in the United States.
FDA Announces Recall of Some Lots of Blood Pressure Medications
One lot of irbesartan and 7 lots of irbesartan and hydrochlorothiazide (HCTZ) combination tablets distributed by Solco Healthcare, a Prinston Pharmaceutical subsidiary are affected.
Tips for Impressing Your Preceptor During Rotations
Students can set themselves apart during rotations, with these tips from a preceptor.
Third Trastuzumab Biosimilar Granted FDA Approval
Officials with the FDA have approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer and HER2 overexpressing gastric cancer.
FDA Approves Third Biosimilar to Herceptin
Officials with the FDA today approved Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar trastuzumab referencing Herceptin.
New Guideline Released for Management of Mild-to-Moderate Ulcerative Colitis
Recommendations outline the efficacy of different types of therapies, dosing regimens, and routes for patients with mild-to-moderate ulcerative colitis.
Pharmacy Week in Review: Walmart to Leave CVS Partnership, Biomarkers Found for Prostate Cancer
A look at last week's top stories in the world of pharmacy.
Trending News Today: FDA Advisory Panel Divided Over Type 1 Diabetes Drug
Trending News Today: FDA Denies Approval to Immunomedics' Breast Cancer Drug
New Treatment Option for Advanced Liver Cancer Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
Fewer Than 1% of US Population Currently Infected With Hepatitis C
Understanding the rate of hepatitis C infection is critical for making strategies to reduce the disease burden among specific populations.
Report Details Impact of Rising Drug Shortages on Hospitals
Average total drug spending per hospital admission increased by 18.5% between FY2015 and FY2017.
FDA Accepts sBLA for Tecentriq, Abraxane Combo for First-Line NSCLC Therapy
Atezolizumab (Tecentriq) plus chemotherapy significantly extended survival in patients with metastatic non-squamous non-small cell lung cancer.
Treatment for Rare Blood Clotting Disorder Shows Efficacy in Phase 3 Study
The target action date for the FDA’s decision on caplacizumab (Cablivi) is February 6, 2019.
Trending News Today: Patient, Medical Groups Launch Campaign Opposing Medicare Changes
Trending News Today: FDA Panel Votes in Favor of Osteoporosis Drug
